COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: Evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression

Recent data from [(11)C]carfentanil ligand-PET indicate that in the human brain, the availability of mu-opioid (MOP) receptor binding sites is affected by the Val(108/158)Met polymorphism of the catechol-O-methyltransferase (COMT) gene. This prompted us to validate the impact of COMT Val(108/158)Met on MOP receptors in human post-mortem brain. [(3)H]DAMGO receptor autoradiography was performed in frontal cortex, basal ganglia, thalamus and cerebellum (8 Met/Met, 6 Met/Val, 3 Val/Val). With respect to genotype, numbers of MOP binding sites in COMT Met(108/158) homozygous and Val(108/158)Met heterozygous cases were higher than in Val(108/158) homozygous. Differences were significant in the caudate nucleus (Val/Met vs. Val/Val), nucleus accumbens (Val/Met vs. Val/Val) and the mediodorsal nucleus of the thalamus (Met/Met vs. Val/Val). In the thalamus, this was corroborated by DAMGO-stimulated [(35)S]GTPgammaS autoradiography. Moreover, stepwise multiple regression taking into account various covariables allowed to confirm the COMT genotype as the most predictive factor in this structure. As a mechanism how COMT might exert its action on MOP receptors, it has been suggested that at least in striatopallidal circuits COMT Val(108/158)Met impacts on enkephalin, which is capable of reciprocally regulating MOP receptor expression. Thus, we assessed preproenkephalin mRNA by in situ hybridization. In the striatum, mRNA levels were significantly higher in COMT Met(108/158) homozygous cases indicating that MOP binding sites and enkephalin are regulated in parallel. Moreover, the transcript was not detectable in the thalamus. Thus, mechanisms other than an enkephalin-dependent receptor turnover must be responsible for COMT-related differences in MOP binding site availability in the human brain.

[1]  M. Kreek,et al.  Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. , 1994, Neuroreport.

[2]  W Zieglgänsberger,et al.  [3h]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain , 2003, Neuroscience.

[3]  A. Parent,et al.  Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys , 1994, Neuroreport.

[4]  J. F. Chen,et al.  Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum , 1993, Neuroscience.

[5]  Susan R. George,et al.  Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission , 1987, Peptides.

[6]  C D Marsden,et al.  Tissue pH as an indicator of mRNA preservation in human post-mortem brain. , 1995, Brain research. Molecular brain research.

[7]  P. Jenner,et al.  Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets , 2002, Neuroscience.

[8]  J. P. Schwartz,et al.  Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Jenner,et al.  Chronicl-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat , 1995, Neuroscience.

[11]  A. Malhotra,et al.  A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. , 2002, The American journal of psychiatry.

[12]  T. Di Paolo,et al.  Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. , 1997, Brain research. Molecular brain research.

[13]  M. Egan,et al.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.

[14]  Anat Biegon,et al.  Regionally selective increases in μ opioid receptor density in the brains of suicide victims , 1990, Brain Research.

[15]  C. Gerfen,et al.  Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior , 1998, Experimental Brain Research.

[16]  B. Kolachana,et al.  Catechol-O-Methyltransferase Genotype and Dopamine Regulation in the Human Brain , 2003, The Journal of Neuroscience.

[17]  Kenneth K Kidd,et al.  Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles , 1999, Biological Psychiatry.

[18]  B. Bloch,et al.  Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum , 2000, The Journal of comparative neurology.

[19]  D. Selley,et al.  In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Lieberman,et al.  Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia , 2002, Biological Psychiatry.

[21]  J. Zubieta,et al.  Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  E. G. Jones,et al.  Distribution of tachykinin- and enkephalin-immunoreactive fibers in the human thalamus , 1989, Brain Research Reviews.

[23]  Stefan Platzer,et al.  Autoradiographic distribution of μ-, δ- and κ1-opioid stimulated [35S]guanylyl-5′-O-(γ-thio)-triphosphate binding in human frontal cortex and cerebellum , 2000, Neuroscience Letters.

[24]  Joshua A. Bueller,et al.  COMT val158met Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor , 2003, Science.

[25]  Y. Hurd,et al.  Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain , 1996, Neuroscience.

[26]  J. Zubieta,et al.  Gender and age influences on human brain mu-opioid receptor binding measured by PET. , 1999, The American journal of psychiatry.

[27]  A. Craig,et al.  Pain mechanisms: labeled lines versus convergence in central processing. , 2003, Annual review of neuroscience.

[28]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[29]  Jacob M. Hiller,et al.  Laminar distribution of the multiple opioid receptors in the human cerebral cortex , 1996, Neurochemical Research.

[30]  Eric J. Simon,et al.  μ-, δ- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer’s disease patients , 2001, Brain Research.

[31]  J. Daunais,et al.  Functional and anatomical localization of mu opioid receptors in the striatum, amygdala, and extended amygdala of the nonhuman primate , 2001, The Journal of comparative neurology.

[32]  S. Ho,et al.  Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. , 1999, Molecular pharmacology.

[33]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[34]  R. Weinshilboum,et al.  Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes , 2004, Molecular Psychiatry.